{"gene":"SMOC2","run_date":"2026-06-10T07:46:36","timeline":{"discoveries":[{"year":2003,"finding":"SMOC2 is a secreted modular glycoprotein containing an EF-hand calcium-binding domain homologous to BM-40, two thyroglobulin-like domains, a follistatin-like domain, and a novel SMOC-specific domain. Recombinant protein analysis showed it has a calcium-dependent conformation.","method":"Recombinant protein expression, domain analysis, calcium-binding characterization","journal":"The Biochemical journal","confidence":"High","confidence_rationale":"Tier 1 / Moderate — direct biochemical characterization of recombinant protein with domain mapping and calcium-binding assay in a dedicated study","pmids":["12741954"],"is_preprint":false},{"year":2006,"finding":"SMOC2 is localized to the extracellular periphery of endothelial cells and secreted into culture medium. Overexpression potentiates VEGF- and bFGF-induced DNA synthesis and angiogenic network formation; siRNA knockdown inhibits endothelial cell proliferation and network formation. In vivo, SMOC2 synergizes with bFGF to promote cell invasion into Matrigel plugs.","method":"Adenoviral overexpression, siRNA knockdown, DNA synthesis assay, in vitro Matrigel angiogenesis assay, subdermal Matrigel plug assay in mice","journal":"The Journal of biological chemistry","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple functional assays (gain and loss of function) in single lab, no mechanistic receptor identification","pmids":["16774925"],"is_preprint":false},{"year":2007,"finding":"SMOC2 promotes growth factor-induced cyclin D1 expression and DNA synthesis by maintaining integrin-linked kinase (ILK) activity during G1. SMOC2 ablation reduces ILK activity without affecting PDGFβR autophosphorylation or MAPK/Akt activation; ectopic hyperactive ILK rescues the mitogenic defect in SMOC2-deficient cells. Cyclin D1 overexpression also rescues G1 progression in SMOC2-deficient cells, placing cyclin D1 downstream of the SMOC2-ILK axis.","method":"siRNA knockdown, ILK activity assay, cyclin D1 expression analysis, epistasis rescue experiments with hyperactive ILK and cyclin D1 overexpression, DNA synthesis assay","journal":"Molecular biology of the cell","confidence":"High","confidence_rationale":"Tier 2 / Strong — reciprocal gain/loss-of-function with epistasis rescue, multiple orthogonal readouts in single lab","pmids":["17989364"],"is_preprint":false},{"year":2008,"finding":"SMOC2 stimulates attachment of primary epidermal keratinocytes and keratinocyte-derived cell lines via αvβ6 and αvβ1 integrins. Integrin blocking antibodies identify these as key receptors. The extracellular calcium-binding domain mediates both cell attachment, focal adhesion formation, and cell migration, but not proliferation.","method":"Cell attachment assay with recombinant protein, integrin-blocking antibody experiments, focal adhesion imaging, migration assay, domain deletion analysis","journal":"Experimental cell research","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — direct biochemical domain mapping combined with functional blocking antibody experiments identifying specific integrin receptors","pmids":["18582461"],"is_preprint":false},{"year":2008,"finding":"SMOC2 expression is transcriptionally repressed by activated aryl-hydrocarbon receptor (AHR) signaling. The SMOC2 promoter contains consensus AHR-binding sites, and AHR ligands (benzo[a]pyrene, TCDD) repress SMOC2 promoter-driven reporter activity in an AHR-dependent manner. TCDD represses Smoc2 mRNA in Ahr+/+ but not Ahr-/- mouse testes in organ culture.","method":"Promoter-reporter assay, AHR ligand treatment, Ahr knockout organ culture, RT-PCR","journal":"Gene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — promoter reporter + genetic (Ahr KO) validation in single lab, two orthogonal approaches","pmids":["19146932"],"is_preprint":false},{"year":2009,"finding":"Smoc2 expression in the fetal gonad is dependent on Hedgehog signaling: organ culture experiments show that Smoc2 expression in testes, mesonephroi, and kidneys requires Hedgehog pathway activity. Smoc2 is expressed in Leydig cells and mesonephroi but not in wildtype ovaries, indicating sexually dimorphic regulation.","method":"Organ culture with Hedgehog pathway inhibition, in situ hybridization, transgenic mutant analysis","journal":"Developmental dynamics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — organ culture functional experiments with pathway inhibition, single lab","pmids":["19842175"],"is_preprint":false},{"year":2011,"finding":"Loss-of-function of SMOC2 in zebrafish (smoc2 knockdown) causes pharyngeal tooth abnormalities resembling the human dentin dysplasia phenotype and reduces expression of key odontogenesis genes dlx2, bmp2, and pitx2, placing SMOC2 upstream of these odontogenic transcription factors.","method":"Morpholino knockdown in zebrafish, in situ hybridization for odontogenesis genes","journal":"American journal of human genetics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — morpholino knockdown with defined molecular phenotype (gene expression changes), single lab","pmids":["22152679"],"is_preprint":false},{"year":2014,"finding":"Smoc2 morpholino knockdown in zebrafish impairs myelopoiesis: hemangioblast development and myeloid progenitor specification are disrupted, and BMP target genes are downregulated in smoc2 morphants, placing Smoc2 upstream of BMP target gene transcription during embryonic myeloid development.","method":"Morpholino knockdown in zebrafish, molecular marker analysis (in situ hybridization), BMP target gene expression analysis","journal":"Developmental dynamics","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — morpholino loss-of-function with epistatic placement upstream of BMP targets, single lab","pmids":["25044883"],"is_preprint":false},{"year":2015,"finding":"SMOC2 expression is induced downstream of L1-ezrin-NF-κB signaling in colorectal cancer cells. SMOC2 is required for L1-mediated increases in cell motility, proliferation under stress, and liver metastasis. SMOC2 promotes a mesenchymal phenotype by decreasing E-cadherin and increasing Snail via integrin-linked kinase (ILK) signaling, and elevates Lgr5 expression.","method":"siRNA knockdown, overexpression, cell motility assay, liver metastasis mouse model, western blot for E-cadherin/Snail/ILK","journal":"Oncogene","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — epistasis (L1→SMOC2→ILK→EMT) established by gain/loss of function and in vivo metastasis model, single lab","pmids":["25915847"],"is_preprint":false},{"year":2017,"finding":"SMOC2 is upregulated in kidney tubular epithelial cells following fibrosis and critically mediates fibroblast-to-myofibroblast transition (FMT): SMOC2 activates stress fiber formation, proliferation, migration, and ECM production in fibroblasts. siRNA targeting SMOC2 attenuates TGFβ1-mediated FMT in vitro and kidney fibrosis in mice.","method":"Genetically manipulated mice (SMOC2 overexpression and knockdown), siRNA in vitro, TGFβ1 stimulation, fibrosis readouts (stress fiber, ECM production, migration)","journal":"JCI insight","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple genetic models (OE and KD mice), in vitro mechanistic validation, in vivo disease model, replicated across models","pmids":["28422762"],"is_preprint":false},{"year":2017,"finding":"Canine brachycephaly is caused by an intronic retrotransposon insertion in SMOC2 that promotes cryptic splice site usage, drastically reducing SMOC2 gene expression. SMOC2 disruption affects facial skeletal length in a dose-dependent manner, accounting for 36% of facial length variation.","method":"Morphometrics, QTL mapping, splice site analysis, transcript quantification in brachycephalic dogs","journal":"Current biology","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — QTL mapping with molecular validation of splice disruption and dose-dependent phenotypic effect, single study","pmids":["28552356"],"is_preprint":false},{"year":2018,"finding":"SMOC2 directly interacts with WNT receptors Fzd6 and LRP6 (co-immunoprecipitation), enhances ligand-receptor interaction with canonical WNT ligands Wnt3a and Wnt10b, and thereby activates the WNT/β-catenin pathway to support endometrial cancer stem cell properties including stemness gene expression (SOX2, OCT4, NANOG) and chemoresistance.","method":"Co-immunoprecipitation assay, luciferase reporter assay, siRNA knockdown, sphere formation assay, western blotting","journal":"EBioMedicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct Co-IP identifying WNT receptor binding partners plus functional reporter assay, single lab","pmids":["30594556"],"is_preprint":false},{"year":2018,"finding":"SMOC2 knockout mice show reduced BLM-induced pulmonary fibrosis with decreased TGFβ1, α-SMA, p-SMAD2, and p-SMAD3 levels. In vitro, SMOC2 upregulation activates fibrosis in MRC-5 cells, and SMOC2 knockdown reduces TGFβ1-stimulated p-SMAD2 and p-SMAD3, placing SMOC2 upstream of the TGFβ1/SMAD2/3 signaling axis.","method":"SMOC2 knockout mice, BLM-induced pulmonary fibrosis model, siRNA knockdown in vitro, western blot for SMAD phosphorylation","journal":"Biomedicine & pharmacotherapy","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO mouse model plus in vitro mechanistic validation, single lab","pmids":["30021376"],"is_preprint":false},{"year":2020,"finding":"A SMOC2 missense mutation (c.1076T>G, Leu359Arg) prevents binding of SMOC2 to COL9A1 and HSPG, and causes the mutant protein to competitively bind BMPR1B, thereby inhibiting BMP-SMAD1/5/9 signaling and producing growth plate defects (disorganized proliferative zones, expanded hypertrophic zones) and short-limbed dwarfism in knock-in mice.","method":"Knock-in mouse model, in vivo and in vitro BMP-SMAD signaling assays, protein binding assays (SMOC2 vs COL9A1/HSPG/BMPR1B interactions)","journal":"Bone","confidence":"High","confidence_rationale":"Tier 1–2 / Moderate — knock-in mouse with mutagenesis, in vivo pathway analysis, and direct binding partner identification by multiple methods","pmids":["33059102"],"is_preprint":false},{"year":2020,"finding":"SMOC2 triggers EMT in kidney epithelial cells through the integrin β3, FAK, and paxillin pathway. Recombinant and enforced SMOC2 expression increases EMT markers, matrix production, proliferation, and migration in RCC cell lines, all inhibited by SMOC2 siRNA.","method":"Recombinant protein treatment, enforced expression, siRNA knockdown, western blot for integrin β3/FAK/paxillin/EMT markers, in vivo xenograft","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain and loss of function plus in vivo validation with pathway identification, single lab","pmids":["35869056"],"is_preprint":false},{"year":2020,"finding":"Smoc2 deficiency in mice results in age-induced periodontal bone loss, impaired bone healing after tooth avulsion, and increased osteoclast activity/bone resorption. Smoc2-GFP reporter marks dental and bone progenitors and is reactivated after tooth injury. COX2 inhibitor (ibuprofen) blocks injury-induced bone loss in Smoc2-/- mice by reducing MMP9.","method":"Smoc2 knockout mouse model, GFP reporter, micro-CT, histology, pharmacological COX2 inhibition, MMP9 analysis","journal":"Scientific reports","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — KO mouse with reporter plus pharmacological rescue, single lab","pmids":["32908163"],"is_preprint":false},{"year":2021,"finding":"Smoc1 and Smoc2 are downstream transcriptional targets of Runx2 in osteoblasts. Runx2 upregulates both genes; knockdown of Smoc1 or Smoc2 inhibits osteoblastogenesis. Smoc2 KO mice show mild craniofacial phenotypes, and Smoc1/Smoc2 double KO mice have severe defects including absent skull, shortened tibiae, and impaired endochondral bone formation.","method":"RNA-sequencing, siRNA knockdown, single and double KO mouse models, skeletal phenotyping","journal":"Communications biology","confidence":"High","confidence_rationale":"Tier 2 / Strong — transcriptomic identification validated by multiple KO models including double KO with severe epistatic phenotype, multiple orthogonal methods","pmids":["34667264"],"is_preprint":false},{"year":2021,"finding":"SMOC2 promotes TGFβ1-induced fibroblast-to-myofibroblast transformation (FMT) in lung fibroblasts by activating AKT and ERK signaling. Inhibition of AKT or ERK reverses the promoting effects of SMOC2 overexpression on proliferation, migration, and FMT.","method":"Overexpression, western blot for p-AKT/p-ERK, AKT/ERK inhibitor rescue experiments, proliferation and migration assays","journal":"Hereditas","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — gain-of-function with pharmacological pathway rescue, single lab","pmids":["34876240"],"is_preprint":false},{"year":2022,"finding":"SMOC2 is secreted by DRG fibroblasts to form a component of the basement membrane surrounding DRG neuron-satellite glial cell units. SMOC2 directly interacts with P2X7 receptor and suppresses ATP-induced P2X7R activation in HEK293 cells. Smoc2 KO increases coupled activation of adjacent DRG neurons in response to nociceptive mechanical stimuli, raising mechanical sensitivity. DRG injection of A740003 (P2X7R antagonist) does not further enhance SMOC2-inhibited coupling, placing SMOC2 upstream of P2X7R-mediated neuronal communication.","method":"Smoc2 KO mice, Smoc2 knockdown, in vivo calcium imaging of DRG neurons, HEK293 P2X7R expression with SMOC2 co-expression, DRG injection of recombinant SMOC2 and P2X7R antagonist, behavioral testing","journal":"The Journal of neuroscience","confidence":"High","confidence_rationale":"Tier 2 / Strong — multiple orthogonal methods (KO, KD, rescue, heterologous expression, pharmacological epistasis, in vivo imaging) in single rigorous study","pmids":["35437277"],"is_preprint":false},{"year":2022,"finding":"SMOC2 promotes migration and invasion of RA fibroblast-like synoviocytes by controlling MYO1C expression through two mechanisms: SOX4-mediated transcriptional regulation and ALKBH5-mediated m6A post-transcriptional modification, leading to cytoskeletal remodeling.","method":"siRNA knockdown, transcriptomics, Co-IP, m6A modification analysis, in vitro migration/invasion assays, in vivo collagen-induced arthritis model with intra-articular shRNA","journal":"Cell death & disease","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — multiple mechanistic layers (transcriptional + m6A) identified in single lab, in vivo validation","pmids":["36513634"],"is_preprint":false},{"year":2023,"finding":"SMOC2 promotes cardiac fibrosis through the ILK/p38 signaling pathway. SMOC2 knockdown inhibits TGFβ-induced cardiac fibroblast transdifferentiation and collagen deposition. ILK overexpression increases p38 phosphorylation and reverses the protective effect of SMOC2 silencing, establishing ILK→p38 as the downstream effector axis.","method":"AAV9-shRNA knockdown in mice, ISO-induced cardiac fibrosis model, TGFβ-treated neonatal fibroblasts, ILK overexpression rescue, western blot for ILK/p-p38","journal":"Frontiers in cardiovascular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — in vivo KD and in vitro epistasis rescue with defined pathway, single lab","pmids":["36935650"],"is_preprint":false},{"year":2023,"finding":"SMOC2 potentiates BMP9-induced osteogenic differentiation in mesenchymal stem cells by enhancing FAK/PI3K/AKT signaling. Integrin β1 interacts with SMOC2 in BMP9-treated cells. GTF2I is enriched at the SMOC2 promoter. SMOC2 knockdown or FAK silencing reduces BMP9-induced osteogenic markers, and LY294002 (PI3K inhibitor) partially abolishes SMOC2-enhanced osteogenesis.","method":"Overexpression, siRNA knockdown, Co-IP (integrin β1–SMOC2), ChIP (GTF2I at SMOC2 promoter), PI3K inhibitor, in vitro osteogenesis assay, ectopic bone formation in vivo","journal":"Stem cells international","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP plus pharmacological epistasis, single lab, multiple supporting assays","pmids":["36698376"],"is_preprint":false},{"year":2025,"finding":"METTL3 increases SMOC2 mRNA stability by adding m6A methylation to SMOC2 transcripts, thereby promoting cardiac fibroblast proliferation and differentiation after hypoxia and cardiac fibrosis post-MI. METTL3 knockdown reduces m6A levels on SMOC2 mRNA and decreases SMOC2 expression, while actinomycin D chase experiments confirm reduced mRNA stability.","method":"meRIP-Seq, actinomycin D mRNA stability assay, AAV9-shRNA in vivo KD, western blot, Masson staining","journal":"Journal of cellular and molecular medicine","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — direct m6A-seq identification of SMOC2 as METTL3 target plus mRNA stability assay and in vivo validation, single lab","pmids":["40913254"],"is_preprint":false},{"year":2026,"finding":"SMOC2 protects renal tubular cells during acute kidney injury by interacting with integrin β3 (ITGB3), which restrains the CCND1-CDK4/6 axis, arresting tubular cells in G1 phase and facilitating DNA repair. SMOC2 KO exacerbates tubular injury, DNA damage, and apoptosis; recombinant SMOC2 treatment ameliorates injury. CDK4/6 inhibitor palbociclib phenocopies SMOC2 protection, confirming the downstream pathway.","method":"SMOC2 KO mice, recombinant SMOC2 treatment, transcriptomic profiling, biochemical binding assays (SMOC2–ITGB3), CDK4/6 inhibitor (palbociclib) rescue, AKI mouse models (AAI and cisplatin)","journal":"Molecular biomedicine","confidence":"High","confidence_rationale":"Tier 1–2 / Strong — KO plus recombinant protein rescue plus pharmacological epistasis, two independent AKI models, transcriptomics + biochemistry","pmids":["41663805"],"is_preprint":false},{"year":2026,"finding":"SMOC2 interacts with integrin αvβ5 in cardiac fibroblasts to inhibit the LKB1/AMPKα/FOXO3 signaling pathway, reducing antioxidant defence and enhancing lipid peroxidation and oxidative stress, thereby promoting cardiac fibrosis after MI. Fibroblast-specific SMOC2 overexpression aggravates fibrosis; SMOC2 KO reduces fibrosis and improves cardiac function.","method":"Fibroblast-specific overexpression, SMOC2 KO mice, LAD ligation MI model, RNA sequencing, metabolomics, Co-IP (SMOC2–integrin αvβ5), western blot for LKB1/AMPKα/FOXO3","journal":"Journal of advanced research","confidence":"Medium","confidence_rationale":"Tier 2 / Moderate — Co-IP binding partner plus multi-omics and in vivo genetic models, single lab","pmids":["41825779"],"is_preprint":false}],"current_model":"SMOC2 is a secreted extracellular calcium-binding matricellular glycoprotein (SPARC/BM-40 family) that regulates cell-matrix interactions, growth factor responses, and cellular signaling through multiple mechanisms: it binds αvβ6/αvβ1 integrins to promote keratinocyte adhesion and migration via its calcium-binding domain; it maintains integrin-linked kinase (ILK) activity to support growth factor-induced cyclin D1 expression and G1 cell cycle progression; it binds WNT co-receptors Fzd6 and LRP6 to potentiate canonical WNT/β-catenin signaling; it interacts with BMPR1B to modulate BMP-SMAD1/5/9 signaling in a concentration- and mutation-dependent manner; it promotes fibroblast-to-myofibroblast transition via TGFβ1/SMAD2/3 and ILK/p38 pathways across multiple tissues; it interacts with integrin β3 (ITGB3) to restrain the CCND1-CDK4/6 axis in renal tubular cells; it drives EMT through integrin β3/FAK/paxillin signaling; it is secreted by DRG fibroblasts to suppress mechanical nociception by interacting with and inhibiting the P2X7 receptor on satellite glial cells; and it is transcriptionally regulated by Runx2 and AHR, and post-transcriptionally stabilized by METTL3-mediated m6A methylation."},"narrative":{"mechanistic_narrative":"SMOC2 is a secreted, calcium-binding modular matricellular glycoprotein of the SPARC/BM-40 family that couples the extracellular matrix to integrin- and growth-factor-driven signaling to regulate cell adhesion, proliferation, fibrosis, and skeletal development [PMID:12741954, PMID:18582461]. Its EF-hand extracellular calcium-binding domain adopts a calcium-dependent conformation and mediates keratinocyte attachment, focal adhesion formation, and migration through αvβ6 and αvβ1 integrins [PMID:12741954, PMID:18582461]. A central, recurring mechanism is engagement of integrin receptors to control cell-cycle progression: SMOC2 sustains integrin-linked kinase (ILK) activity to drive growth-factor-induced cyclin D1 expression and G1 progression [PMID:17989364], whereas in renal tubular cells it binds integrin β3 (ITGB3) to restrain the CCND1-CDK4/6 axis and arrest cells in G1 to permit DNA repair [PMID:41663805]. Through integrin β3/FAK/paxillin signaling and ILK-dependent suppression of E-cadherin, SMOC2 drives epithelial-mesenchymal transition and tumor cell motility [PMID:25915847, PMID:35869056]. SMOC2 is a major pro-fibrotic effector across kidney, lung, and heart, mediating TGFβ1/SMAD2/3- and ILK/p38-dependent fibroblast-to-myofibroblast transition [PMID:28422762, PMID:30021376, PMID:36935650]. It also potentiates canonical WNT/β-catenin signaling by binding the co-receptors Fzd6 and LRP6 and enhancing WNT ligand-receptor interaction [PMID:30594556], and modulates BMP signaling: a Leu359Arg missense mutation that abolishes COL9A1/HSPG binding causes SMOC2 to competitively bind BMPR1B, inhibit BMP-SMAD1/5/9 signaling, and produce growth-plate defects and short-limbed dwarfism in knock-in mice [PMID:33059102]. SMOC2 is a transcriptional target of Runx2 required for osteoblastogenesis [PMID:34667264] and is post-transcriptionally stabilized by METTL3-mediated m6A methylation [PMID:40913254]. In sensory ganglia, fibroblast-secreted SMOC2 binds and inhibits the P2X7 receptor on satellite glial cells to suppress coupled nociceptive neuronal activation [PMID:35437277].","teleology":[{"year":2003,"claim":"Established SMOC2 as a secreted modular glycoprotein and defined its domain architecture, providing the structural basis for its matricellular function.","evidence":"Recombinant protein expression with domain mapping and calcium-binding characterization","pmids":["12741954"],"confidence":"High","gaps":["No receptor or binding partner identified at this stage","Functional consequence of calcium-dependent conformation untested"]},{"year":2006,"claim":"Showed SMOC2 functionally potentiates growth-factor-induced endothelial proliferation and angiogenesis, moving it from a structural ECM component to a modulator of growth-factor responses.","evidence":"Adenoviral overexpression, siRNA knockdown, Matrigel angiogenesis and plug assays in mice","pmids":["16774925"],"confidence":"Medium","gaps":["No receptor mediating the angiogenic effect identified","Mechanism linking SMOC2 to VEGF/bFGF signaling unresolved"]},{"year":2007,"claim":"Defined the SMOC2-ILK-cyclin D1 axis, explaining how SMOC2 promotes G1 cell-cycle progression downstream of growth factors.","evidence":"siRNA knockdown with ILK activity assay and epistasis rescue by hyperactive ILK and cyclin D1","pmids":["17989364"],"confidence":"High","gaps":["How SMOC2 maintains ILK activity mechanistically unclear","Upstream receptor coupling SMOC2 to ILK not defined here"]},{"year":2008,"claim":"Identified the specific integrin receptors (αvβ6, αvβ1) and the calcium-binding domain as the structural determinant for SMOC2-mediated adhesion and migration, separating adhesion/migration from proliferation.","evidence":"Cell attachment, integrin blocking antibodies, focal adhesion imaging, and domain deletion in keratinocytes","pmids":["18582461"],"confidence":"High","gaps":["Did not connect integrin engagement to the ILK/cyclin D1 axis","Cell-type specificity of integrin usage untested"]},{"year":2008,"claim":"Placed SMOC2 transcription under negative control of AHR signaling, identifying an environmental/ligand-responsive regulatory input.","evidence":"Promoter-reporter assay, AHR ligand treatment, and Ahr-knockout organ culture","pmids":["19146932"],"confidence":"Medium","gaps":["Direct AHR binding to the SMOC2 promoter not shown by ChIP","Physiological context of AHR repression unclear"]},{"year":2009,"claim":"Showed Smoc2 expression in the fetal gonad/kidney is Hedgehog-dependent and sexually dimorphic, embedding SMOC2 in developmental signaling pathways.","evidence":"Organ culture with Hedgehog inhibition, in situ hybridization, transgenic mutant analysis","pmids":["19842175"],"confidence":"Medium","gaps":["Direct vs indirect Hedgehog regulation not distinguished","Functional consequence of gonadal Smoc2 expression untested"]},{"year":2011,"claim":"Established SMOC2 as functionally required for tooth development, placing it upstream of odontogenic transcription factors and linking it to human dentin dysplasia.","evidence":"Morpholino knockdown in zebrafish with in situ hybridization for dlx2, bmp2, pitx2","pmids":["22152679"],"confidence":"Medium","gaps":["Molecular intermediary between SMOC2 and odontogenic genes unknown","Morpholino approach lacks genetic confirmation"]},{"year":2014,"claim":"Extended SMOC2's developmental role to embryonic myelopoiesis and placed it upstream of BMP target gene transcription.","evidence":"Morpholino knockdown in zebrafish with marker and BMP target gene analysis","pmids":["25044883"],"confidence":"Medium","gaps":["Mechanism linking SMOC2 to BMP signaling not biochemically defined","Conservation in mammalian hematopoiesis untested"]},{"year":2015,"claim":"Identified SMOC2 as a pro-metastatic effector in colorectal cancer that drives EMT via ILK signaling, integrating its adhesion biology with tumor progression.","evidence":"siRNA/overexpression, motility assays, liver metastasis mouse model, EMT marker western blot","pmids":["25915847"],"confidence":"Medium","gaps":["Direct receptor engagement in colorectal cells not shown","Single-lab in vivo metastasis model"]},{"year":2017,"claim":"Established SMOC2 as a critical mediator of fibroblast-to-myofibroblast transition and kidney fibrosis downstream of TGFβ1, defining its central pro-fibrotic role.","evidence":"SMOC2 overexpression and knockdown mice, siRNA in vitro, TGFβ1 stimulation, fibrosis readouts","pmids":["28422762"],"confidence":"High","gaps":["Receptor coupling SMOC2 to TGFβ1/SMAD response not defined here","Whether effect is cell-autonomous to fibroblasts unresolved"]},{"year":2017,"claim":"Demonstrated dose-dependent control of facial skeletal length by SMOC2 expression via a natural splice-disrupting insertion, providing in vivo evidence for SMOC2 in craniofacial morphogenesis.","evidence":"QTL mapping, splice analysis, transcript quantification in brachycephalic dogs","pmids":["28552356"],"confidence":"Medium","gaps":["Molecular pathway connecting SMOC2 dosage to bone length unclear","Correlational genetics rather than direct mechanism"]},{"year":2018,"claim":"Identified direct SMOC2 binding to WNT co-receptors Fzd6 and LRP6 and potentiation of canonical WNT signaling, expanding SMOC2's receptor repertoire beyond integrins.","evidence":"Co-immunoprecipitation, luciferase reporter, sphere formation in endometrial cancer cells","pmids":["30594556"],"confidence":"Medium","gaps":["Reciprocal/endogenous interaction validation limited","Binding interface on SMOC2 not mapped"]},{"year":2018,"claim":"Placed SMOC2 upstream of the TGFβ1/SMAD2/3 axis in pulmonary fibrosis, generalizing its pro-fibrotic mechanism to a second organ.","evidence":"SMOC2 knockout mice, BLM fibrosis model, siRNA in vitro, SMAD phosphorylation western blot","pmids":["30021376"],"confidence":"Medium","gaps":["How SMOC2 modulates SMAD phosphorylation mechanistically unknown","Receptor not identified"]},{"year":2020,"claim":"Resolved a disease-causing missense mutation mechanism in which loss of COL9A1/HSPG binding redirects SMOC2 to competitively inhibit BMPR1B, linking SMOC2 to BMP-SMAD1/5/9 signaling and skeletal dysplasia.","evidence":"Knock-in mouse, in vivo/in vitro BMP-SMAD assays, SMOC2-COL9A1/HSPG/BMPR1B binding assays","pmids":["33059102"],"confidence":"High","gaps":["Whether wild-type SMOC2 normally regulates BMPR1B unclear","Stoichiometry of competitive binding not quantified"]},{"year":2020,"claim":"Defined an integrin β3/FAK/paxillin pathway through which SMOC2 drives EMT and matrix production in renal cancer cells.","evidence":"Recombinant protein, enforced expression, siRNA, pathway western blots, xenograft","pmids":["35869056"],"confidence":"Medium","gaps":["Direct SMOC2-ITGB3 binding not biochemically shown here","Single-lab pathway assignment"]},{"year":2020,"claim":"Established SMOC2 as a marker and functional regulator of dental/bone progenitors and bone homeostasis, with loss causing periodontal bone loss and excess osteoclast activity.","evidence":"Smoc2 knockout, GFP reporter, micro-CT, COX2 inhibitor rescue, MMP9 analysis","pmids":["32908163"],"confidence":"Medium","gaps":["Molecular pathway linking SMOC2 to osteoclast/MMP9 control unclear","Cell-autonomous vs paracrine action undefined"]},{"year":2021,"claim":"Placed Smoc2 downstream of Runx2 as a transcriptional target required for osteoblastogenesis, with double Smoc1/Smoc2 loss producing severe skeletal defects.","evidence":"RNA-seq, siRNA, single and double KO mouse skeletal phenotyping","pmids":["34667264"],"confidence":"High","gaps":["Functional redundancy of Smoc1/Smoc2 not molecularly dissected","Downstream effectors in osteoblasts unidentified"]},{"year":2021,"claim":"Identified AKT and ERK as effector pathways for SMOC2-driven lung fibroblast-to-myofibroblast transformation, broadening its pro-fibrotic signaling outputs.","evidence":"Overexpression with AKT/ERK inhibitor rescue and proliferation/migration assays","pmids":["34876240"],"confidence":"Medium","gaps":["Upstream receptor not defined","Gain-of-function only"]},{"year":2022,"claim":"Demonstrated SMOC2 is secreted into the DRG basement membrane and directly binds and inhibits the P2X7 receptor on satellite glia to suppress mechanical nociception, revealing a neuro-immune signaling role.","evidence":"Smoc2 KO/KD, in vivo calcium imaging, HEK293 P2X7R co-expression, pharmacological epistasis, behavior","pmids":["35437277"],"confidence":"High","gaps":["Structural basis of SMOC2-P2X7R inhibition not resolved","Generality beyond DRG untested"]},{"year":2022,"claim":"Revealed dual transcriptional (SOX4) and m6A (ALKBH5) control of MYO1C as the mechanism for SMOC2-driven synoviocyte invasion in rheumatoid arthritis.","evidence":"siRNA, transcriptomics, Co-IP, m6A analysis, migration/invasion assays, CIA model","pmids":["36513634"],"confidence":"Medium","gaps":["How SMOC2 controls SOX4/ALKBH5 mechanistically unclear","Multiple layers attributed in a single study"]},{"year":2023,"claim":"Defined the ILK/p38 axis as the downstream effector of SMOC2-driven cardiac fibrosis, extending its pro-fibrotic role to heart.","evidence":"AAV9-shRNA in mice, ISO fibrosis model, TGFβ-treated fibroblasts, ILK overexpression rescue","pmids":["36935650"],"confidence":"Medium","gaps":["Receptor linking SMOC2 to ILK in cardiac fibroblasts unknown","Single-lab assignment"]},{"year":2023,"claim":"Showed SMOC2 potentiates BMP9 osteogenesis through integrin β1-coupled FAK/PI3K/AKT signaling and is itself transcriptionally controlled by GTF2I, integrating integrin engagement with osteogenic differentiation.","evidence":"Overexpression/siRNA, Co-IP (integrin β1), ChIP (GTF2I), PI3K inhibitor, in vivo bone formation","pmids":["36698376"],"confidence":"Medium","gaps":["Direct integrin β1-SMOC2 interface not mapped","Single-lab pathway"]},{"year":2025,"claim":"Identified METTL3-mediated m6A methylation as a stabilizer of SMOC2 mRNA driving post-MI cardiac fibrosis, adding a post-transcriptional layer to SMOC2 regulation.","evidence":"meRIP-Seq, actinomycin D stability assay, AAV9-shRNA in vivo, Masson staining","pmids":["40913254"],"confidence":"Medium","gaps":["m6A reader mediating stabilization not identified","Single-lab finding"]},{"year":2026,"claim":"Showed SMOC2 binds integrin β3 to restrain the CCND1-CDK4/6 axis and arrest renal tubular cells in G1, protecting against acute kidney injury — a cytoprotective, anti-proliferative role contrasting its pro-proliferative ILK action.","evidence":"SMOC2 KO, recombinant protein rescue, transcriptomics, SMOC2-ITGB3 binding, palbociclib epistasis, two AKI models","pmids":["41663805"],"confidence":"High","gaps":["Reconciliation with SMOC2's pro-proliferative ILK/cyclin D1 role across cell types unresolved","Determinants of pro- vs anti-proliferative output unknown"]},{"year":2026,"claim":"Identified SMOC2-integrin αvβ5 engagement as an inhibitor of LKB1/AMPKα/FOXO3 antioxidant signaling that enhances lipid peroxidation and post-MI cardiac fibrosis, linking SMOC2 to redox/metabolic control.","evidence":"Fibroblast-specific overexpression, SMOC2 KO, LAD ligation MI, RNA-seq, metabolomics, Co-IP (αvβ5)","pmids":["41825779"],"confidence":"Medium","gaps":["Direct binding interface with αvβ5 not mapped","Single-lab multi-omics correlation"]},{"year":null,"claim":"It remains unclear what molecular switch determines whether integrin-engaged SMOC2 drives pro-proliferative ILK/cyclin D1 signaling versus anti-proliferative CCND1-CDK4/6 restraint, and how its many integrin partners (αvβ6, αvβ1, β3, β1, αvβ5) are selected in a given cell type.","evidence":"","pmids":[],"confidence":"Medium","gaps":["No unified structural model of SMOC2-integrin selectivity","Context-dependent opposite cell-cycle outcomes unexplained","No high-resolution structure of SMOC2 bound to any receptor"]}],"mechanism_profile":{"molecular_activity":[{"term_id":"GO:0098772","term_label":"molecular function regulator activity","supporting_discovery_ids":[2,11,13,18,23]},{"term_id":"GO:0008092","term_label":"cytoskeletal protein binding","supporting_discovery_ids":[3,14]},{"term_id":"GO:0005198","term_label":"structural molecule activity","supporting_discovery_ids":[0,18]},{"term_id":"GO:0060089","term_label":"molecular transducer activity","supporting_discovery_ids":[3,14,23,24]}],"localization":[{"term_id":"GO:0005576","term_label":"extracellular region","supporting_discovery_ids":[0,1,18]},{"term_id":"GO:0031012","term_label":"extracellular matrix","supporting_discovery_ids":[13,18]}],"pathway":[{"term_id":"R-HSA-162582","term_label":"Signal Transduction","supporting_discovery_ids":[11,13,20,24]},{"term_id":"R-HSA-1474244","term_label":"Extracellular matrix organization","supporting_discovery_ids":[9,12,20]},{"term_id":"R-HSA-1266738","term_label":"Developmental Biology","supporting_discovery_ids":[6,13,16]},{"term_id":"R-HSA-1640170","term_label":"Cell Cycle","supporting_discovery_ids":[2,23]},{"term_id":"R-HSA-1643685","term_label":"Disease","supporting_discovery_ids":[8,13,14,23]}],"complexes":[],"partners":["ITGB3","ITGB1","ITGAV","FZD6","LRP6","BMPR1B","P2RX7","COL9A1"],"other_free_text":[]}},"prefetch_data":{"uniprot":{"accession":"Q9H3U7","full_name":"SPARC-related modular calcium-binding protein 2","aliases":["Secreted modular calcium-binding protein 2","SMOC-2","Smooth muscle-associated protein 2","SMAP-2"],"length_aa":446,"mass_kda":49.7,"function":"Promotes matrix assembly and cell adhesiveness (By similarity). Can stimulate endothelial cell proliferation, migration, as well as angiogenesis","subcellular_location":"Secreted, extracellular space, extracellular matrix, basement membrane","url":"https://www.uniprot.org/uniprotkb/Q9H3U7/entry"},"depmap":{"release":"DepMap","has_data":true,"is_common_essential":false,"resolved_as":"","url":"https://depmap.org/portal/gene/SMOC2","classification":"Not Classified","n_dependent_lines":0,"n_total_lines":1208,"dependency_fraction":0.0},"opencell":{"profiled":false,"resolved_as":"","ensg_id":"","cell_line_id":"","localizations":[],"interactors":[{"gene":"RHOA","stoichiometry":0.2}],"url":"https://opencell.sf.czbiohub.org/search/SMOC2","total_profiled":1310},"omim":[{"mim_id":"609187","title":"SUCCINYL-CoA:GLUTARATE-CoA TRANSFERASE; SUGCT","url":"https://www.omim.org/entry/609187"},{"mim_id":"607223","title":"SPARC-RELATED MODULAR CALCIUM-BINDING PROTEIN 2; SMOC2","url":"https://www.omim.org/entry/607223"},{"mim_id":"125400","title":"DENTIN DYSPLASIA, TYPE IA; DTDP1A","url":"https://www.omim.org/entry/125400"}],"hpa":{"profiled":true,"resolved_as":"","reliability":"","locations":[],"tissue_specificity":"Tissue enhanced","tissue_distribution":"Detected in many","driving_tissues":[{"tissue":"blood vessel","ntpm":407.9}],"url":"https://www.proteinatlas.org/search/SMOC2"},"hgnc":{"alias_symbol":["SMAP2"],"prev_symbol":[]},"alphafold":{"accession":"Q9H3U7","domains":[{"cath_id":"3.30.60.30","chopping":"41-82","consensus_level":"medium","plddt":84.154,"start":41,"end":82},{"cath_id":"4.10.800.10","chopping":"90-148","consensus_level":"medium","plddt":82.3686,"start":90,"end":148},{"cath_id":"4.10.800.10","chopping":"215-290","consensus_level":"high","plddt":77.0007,"start":215,"end":290},{"cath_id":"1.10.238.10","chopping":"294-414","consensus_level":"high","plddt":82.5721,"start":294,"end":414}],"viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9H3U7","model_url":"https://alphafold.ebi.ac.uk/files/AF-Q9H3U7-F1-model_v6.cif","pae_url":"https://alphafold.ebi.ac.uk/files/AF-Q9H3U7-F1-predicted_aligned_error_v6.png","plddt_mean":73.62},"mouse_models":{"mgi_url":"https://www.informatics.jax.org/marker/summary?nomen=SMOC2","jax_strain_url":"https://www.jax.org/strain/search?query=SMOC2"},"sequence":{"accession":"Q9H3U7","fasta_url":"https://rest.uniprot.org/uniprotkb/Q9H3U7.fasta","uniprot_url":"https://www.uniprot.org/uniprotkb/Q9H3U7/entry","alphafold_viewer_url":"https://alphafold.ebi.ac.uk/entry/Q9H3U7"}},"corpus_meta":[{"pmid":"12741954","id":"PMC_12741954","title":"Characterization of SMOC-2, a modular extracellular calcium-binding protein.","date":"2003","source":"The Biochemical journal","url":"https://pubmed.ncbi.nlm.nih.gov/12741954","citation_count":111,"is_preprint":false},{"pmid":"16774925","id":"PMC_16774925","title":"The novel SPARC family member SMOC-2 potentiates angiogenic growth factor activity.","date":"2006","source":"The Journal of biological chemistry","url":"https://pubmed.ncbi.nlm.nih.gov/16774925","citation_count":106,"is_preprint":false},{"pmid":"28552356","id":"PMC_28552356","title":"Canine Brachycephaly Is Associated with a Retrotransposon-Mediated Missplicing of SMOC2.","date":"2017","source":"Current biology : CB","url":"https://pubmed.ncbi.nlm.nih.gov/28552356","citation_count":88,"is_preprint":false},{"pmid":"22152679","id":"PMC_22152679","title":"Homozygosity mapping and candidate prioritization identify mutations, missed by whole-exome sequencing, in SMOC2, causing major dental developmental defects.","date":"2011","source":"American journal of human genetics","url":"https://pubmed.ncbi.nlm.nih.gov/22152679","citation_count":81,"is_preprint":false},{"pmid":"30594556","id":"PMC_30594556","title":"Targeting cancer stem cell signature gene SMOC-2 Overcomes chemoresistance and inhibits cell proliferation of endometrial carcinoma.","date":"2018","source":"EBioMedicine","url":"https://pubmed.ncbi.nlm.nih.gov/30594556","citation_count":74,"is_preprint":false},{"pmid":"28422762","id":"PMC_28422762","title":"Silencing SMOC2 ameliorates kidney fibrosis by inhibiting fibroblast to myofibroblast transformation.","date":"2017","source":"JCI insight","url":"https://pubmed.ncbi.nlm.nih.gov/28422762","citation_count":69,"is_preprint":false},{"pmid":"19890347","id":"PMC_19890347","title":"Genome-wide association study of generalized vitiligo in an isolated European founder population identifies SMOC2, in close proximity to IDDM8.","date":"2009","source":"The Journal of investigative dermatology","url":"https://pubmed.ncbi.nlm.nih.gov/19890347","citation_count":68,"is_preprint":false},{"pmid":"25915847","id":"PMC_25915847","title":"Induction of the intestinal stem cell signature gene SMOC-2 is required for L1-mediated colon cancer progression.","date":"2015","source":"Oncogene","url":"https://pubmed.ncbi.nlm.nih.gov/25915847","citation_count":58,"is_preprint":false},{"pmid":"17989364","id":"PMC_17989364","title":"The SPARC-related factor SMOC-2 promotes growth factor-induced cyclin D1 expression and DNA synthesis via integrin-linked kinase.","date":"2007","source":"Molecular biology of the cell","url":"https://pubmed.ncbi.nlm.nih.gov/17989364","citation_count":57,"is_preprint":false},{"pmid":"18582461","id":"PMC_18582461","title":"The widely expressed extracellular matrix protein SMOC-2 promotes keratinocyte attachment and migration.","date":"2008","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/18582461","citation_count":56,"is_preprint":false},{"pmid":"19842175","id":"PMC_19842175","title":"Developmental expression of Smoc1 and Smoc2 suggests potential roles in fetal gonad and reproductive tract differentiation.","date":"2009","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/19842175","citation_count":51,"is_preprint":false},{"pmid":"30021376","id":"PMC_30021376","title":"Suppression of SMOC2 reduces bleomycin (BLM)-induced pulmonary fibrosis by inhibition of TGF-β1/SMADs pathway.","date":"2018","source":"Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie","url":"https://pubmed.ncbi.nlm.nih.gov/30021376","citation_count":42,"is_preprint":false},{"pmid":"36513634","id":"PMC_36513634","title":"SMOC2 promotes aggressive behavior of fibroblast-like synoviocytes in rheumatoid arthritis through transcriptional and post-transcriptional regulating MYO1C.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/36513634","citation_count":37,"is_preprint":false},{"pmid":"23317772","id":"PMC_23317772","title":"Recessive oligodontia linked to a homozygous loss-of-function mutation in the SMOC2 gene.","date":"2013","source":"Archives of oral biology","url":"https://pubmed.ncbi.nlm.nih.gov/23317772","citation_count":36,"is_preprint":false},{"pmid":"28018113","id":"PMC_28018113","title":"Smoc2 potentiates proliferation of hepatocellular carcinoma cells via promotion of cell cycle progression.","date":"2016","source":"World journal of gastroenterology","url":"https://pubmed.ncbi.nlm.nih.gov/28018113","citation_count":30,"is_preprint":false},{"pmid":"32355542","id":"PMC_32355542","title":"ARNTL2 knockdown suppressed the invasion and migration of colon carcinoma: decreased SMOC2-EMT expression through inactivation of PI3K/AKT pathway.","date":"2020","source":"American journal of translational research","url":"https://pubmed.ncbi.nlm.nih.gov/32355542","citation_count":30,"is_preprint":false},{"pmid":"34667264","id":"PMC_34667264","title":"Smoc1 and Smoc2 regulate bone formation as downstream molecules of Runx2.","date":"2021","source":"Communications biology","url":"https://pubmed.ncbi.nlm.nih.gov/34667264","citation_count":29,"is_preprint":false},{"pmid":"20965805","id":"PMC_20965805","title":"SMOC2 gene variant and the risk of vitiligo in Jordanian Arabs.","date":"2010","source":"European journal of dermatology : EJD","url":"https://pubmed.ncbi.nlm.nih.gov/20965805","citation_count":22,"is_preprint":false},{"pmid":"23463390","id":"PMC_23463390","title":"Variants in PTPN22 and SMOC2 genes and the risk of thyroid disease in the Jordanian Arab population.","date":"2013","source":"Endocrine","url":"https://pubmed.ncbi.nlm.nih.gov/23463390","citation_count":22,"is_preprint":false},{"pmid":"35869056","id":"PMC_35869056","title":"SMOC2 promotes an epithelial-mesenchymal transition and a pro-metastatic phenotype in epithelial cells of renal cell carcinoma origin.","date":"2022","source":"Cell death & disease","url":"https://pubmed.ncbi.nlm.nih.gov/35869056","citation_count":21,"is_preprint":false},{"pmid":"25044883","id":"PMC_25044883","title":"Smoc2 modulates embryonic myelopoiesis during zebrafish development.","date":"2014","source":"Developmental dynamics : an official publication of the American Association of Anatomists","url":"https://pubmed.ncbi.nlm.nih.gov/25044883","citation_count":21,"is_preprint":false},{"pmid":"32908163","id":"PMC_32908163","title":"Deficiency of the SMOC2 matricellular protein impairs bone healing and produces age-dependent bone loss.","date":"2020","source":"Scientific reports","url":"https://pubmed.ncbi.nlm.nih.gov/32908163","citation_count":19,"is_preprint":false},{"pmid":"33059102","id":"PMC_33059102","title":"A SMOC2 variant inhibits BMP signaling by competitively binding to BMPR1B and causes growth plate defects.","date":"2020","source":"Bone","url":"https://pubmed.ncbi.nlm.nih.gov/33059102","citation_count":19,"is_preprint":false},{"pmid":"34876240","id":"PMC_34876240","title":"TGF-β1/SMOC2/AKT and ERK axis regulates proliferation, migration, and fibroblast to myofibroblast transformation in lung fibroblast, contributing with the asthma progression.","date":"2021","source":"Hereditas","url":"https://pubmed.ncbi.nlm.nih.gov/34876240","citation_count":19,"is_preprint":false},{"pmid":"35437277","id":"PMC_35437277","title":"Fibroblastic SMOC2 Suppresses Mechanical Nociception by Inhibiting Coupled Activation of Primary Sensory Neurons.","date":"2022","source":"The Journal of neuroscience : the official journal of the Society for Neuroscience","url":"https://pubmed.ncbi.nlm.nih.gov/35437277","citation_count":17,"is_preprint":false},{"pmid":"19146932","id":"PMC_19146932","title":"The developmentally-regulated Smoc2 gene is repressed by Aryl-hydrocarbon receptor (Ahr) signaling.","date":"2008","source":"Gene","url":"https://pubmed.ncbi.nlm.nih.gov/19146932","citation_count":16,"is_preprint":false},{"pmid":"28356709","id":"PMC_28356709","title":"The SPARC-related modular calcium binding protein 2 (SMOC2) gene polymorphism in primary glaucoma: a case-control study.","date":"2017","source":"Clinical ophthalmology (Auckland, N.Z.)","url":"https://pubmed.ncbi.nlm.nih.gov/28356709","citation_count":16,"is_preprint":false},{"pmid":"36935650","id":"PMC_36935650","title":"Suppression of SMOC2 alleviates myocardial fibrosis via the ILK/p38 pathway.","date":"2023","source":"Frontiers in cardiovascular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36935650","citation_count":14,"is_preprint":false},{"pmid":"35397056","id":"PMC_35397056","title":"microRNA-148a in Exosomes Derived from Bone Marrow Mesenchymal Stem Cells Alleviates Cardiomyocyte Apoptosis in Atrial Fibrillation by Inhibiting SMOC2.","date":"2022","source":"Molecular biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/35397056","citation_count":14,"is_preprint":false},{"pmid":"37700850","id":"PMC_37700850","title":"SMOC2 promoted vascular smooth muscle cell proliferation, migration, and extracellular matrix degradation by activating BMP/TGF-β1 signaling pathway.","date":"2023","source":"Journal of clinical biochemistry and nutrition","url":"https://pubmed.ncbi.nlm.nih.gov/37700850","citation_count":9,"is_preprint":false},{"pmid":"37465345","id":"PMC_37465345","title":"SMOC2 plays a role in heart failure via regulating TGF-β1/Smad3 pathway-mediated autophagy.","date":"2023","source":"Open medicine (Warsaw, Poland)","url":"https://pubmed.ncbi.nlm.nih.gov/37465345","citation_count":8,"is_preprint":false},{"pmid":"35662010","id":"PMC_35662010","title":"LncRNA LINC01857 drives pancreatic adenocarcinoma progression via modulating miR-19a-3p/SMOC2.","date":"2022","source":"Clinics (Sao Paulo, Brazil)","url":"https://pubmed.ncbi.nlm.nih.gov/35662010","citation_count":7,"is_preprint":false},{"pmid":"28678915","id":"PMC_28678915","title":"Increased expression of ID2, PRELP and SMOC2 genes in patients with endometriosis.","date":"2017","source":"Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas","url":"https://pubmed.ncbi.nlm.nih.gov/28678915","citation_count":6,"is_preprint":false},{"pmid":"36698376","id":"PMC_36698376","title":"Matricellular Protein SMOC2 Potentiates BMP9-Induced Osteogenic Differentiation in Mesenchymal Stem Cells through the Enhancement of FAK/PI3K/AKT Signaling.","date":"2023","source":"Stem cells international","url":"https://pubmed.ncbi.nlm.nih.gov/36698376","citation_count":6,"is_preprint":false},{"pmid":"38612855","id":"PMC_38612855","title":"FTO Positively Regulates Odontoblastic Differentiation via SMOC2 in Human Stem Cells from the Apical Papilla under Inflammatory Microenvironment.","date":"2024","source":"International journal of molecular sciences","url":"https://pubmed.ncbi.nlm.nih.gov/38612855","citation_count":6,"is_preprint":false},{"pmid":"39791204","id":"PMC_39791204","title":"SMOC2 promotes microglia activity and neuroinflammation in Alzheimer's disease.","date":"2025","source":"Journal of Alzheimer's disease : JAD","url":"https://pubmed.ncbi.nlm.nih.gov/39791204","citation_count":5,"is_preprint":false},{"pmid":"29233684","id":"PMC_29233684","title":"mmu-miR-1963 negatively regulates the ameloblast differentiation of LS8 cell line by directly targeting Smoc2 3'UTR.","date":"2017","source":"Experimental cell research","url":"https://pubmed.ncbi.nlm.nih.gov/29233684","citation_count":5,"is_preprint":false},{"pmid":"36250097","id":"PMC_36250097","title":"SMOC2 gene interacts with APOL1 in the development of end-stage kidney disease: A genome-wide association study.","date":"2022","source":"Frontiers in medicine","url":"https://pubmed.ncbi.nlm.nih.gov/36250097","citation_count":5,"is_preprint":false},{"pmid":"39253355","id":"PMC_39253355","title":"Gene Misexpression in a Smoc2+ve/Sox2-Low Population in Juvenile Prop1-Mutant Pituitary Gland.","date":"2024","source":"Journal of the Endocrine Society","url":"https://pubmed.ncbi.nlm.nih.gov/39253355","citation_count":3,"is_preprint":false},{"pmid":"40913254","id":"PMC_40913254","title":"METTL3 Silencing Suppresses Cardiac Fibrosis Post Myocardial Infarction via m6A Modification of SMOC2.","date":"2025","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/40913254","citation_count":3,"is_preprint":false},{"pmid":"35543855","id":"PMC_35543855","title":"MicroRNA-19a-3p Acts as an Oncogene in Gastric Cancer and Exerts the Effect by Targeting SMOC2.","date":"2022","source":"Applied biochemistry and biotechnology","url":"https://pubmed.ncbi.nlm.nih.gov/35543855","citation_count":2,"is_preprint":false},{"pmid":"39717447","id":"PMC_39717447","title":"SMOC2, OGN, FCN3, and SERPINA3 could be biomarkers for the evaluation of acute decompensated heart failure caused by venous congestion.","date":"2024","source":"Frontiers in cardiovascular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/39717447","citation_count":2,"is_preprint":false},{"pmid":"39697889","id":"PMC_39697889","title":"Analysis of SMOC2 gene variants in familial and non-familial primary open angle glaucoma Pakistani patients.","date":"2024","source":"International journal of ophthalmology","url":"https://pubmed.ncbi.nlm.nih.gov/39697889","citation_count":1,"is_preprint":false},{"pmid":"39510490","id":"PMC_39510490","title":"Spatial and temporal expression analysis of BMP signal modifiers, Smoc1 and Smoc2, from postnatal to adult developmental stages in the mouse testis.","date":"2024","source":"Gene expression patterns : GEP","url":"https://pubmed.ncbi.nlm.nih.gov/39510490","citation_count":1,"is_preprint":false},{"pmid":"40181364","id":"PMC_40181364","title":"Role of SMOC2 in adenomyosis: implications for ECM remodeling and EMT pathogenesis.","date":"2025","source":"BMC women's health","url":"https://pubmed.ncbi.nlm.nih.gov/40181364","citation_count":1,"is_preprint":false},{"pmid":"41217531","id":"PMC_41217531","title":"SMOC2 promotes peritoneal metastasis of gastric cancer involving Wnt/β-catenin pathway modulation and inducing angiogenesis.","date":"2025","source":"Clinical and experimental medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41217531","citation_count":0,"is_preprint":false},{"pmid":"41714037","id":"PMC_41714037","title":"The Runx2-SMOC axis in skeletal development: Expanding roles of Smoc1 and Smoc2 in development and disease.","date":"2026","source":"Journal of oral biosciences","url":"https://pubmed.ncbi.nlm.nih.gov/41714037","citation_count":0,"is_preprint":false},{"pmid":"41663805","id":"PMC_41663805","title":"Matricellular protein SMOC2 safeguards tubular integrity in acute kidney injury via integrin β3-dependent inhibition of CCND1-CDK4/6 axis.","date":"2026","source":"Molecular biomedicine","url":"https://pubmed.ncbi.nlm.nih.gov/41663805","citation_count":0,"is_preprint":false},{"pmid":"41825779","id":"PMC_41825779","title":"SMOC2 accelerates myocardial fibrosis following myocardial infarction by promoting lipid peroxidation through inhibition of the LKB1/AMPKα/FOXO3 pathway.","date":"2026","source":"Journal of advanced research","url":"https://pubmed.ncbi.nlm.nih.gov/41825779","citation_count":0,"is_preprint":false},{"pmid":"41408627","id":"PMC_41408627","title":"WNT10A-SMOC2-LRP4 network affects permanent tooth development via potential tooth-bone interaction.","date":"2025","source":"BMC oral health","url":"https://pubmed.ncbi.nlm.nih.gov/41408627","citation_count":0,"is_preprint":false},{"pmid":"41998832","id":"PMC_41998832","title":"Bioinformatics and Immunohistochemistry Reveal the Diagnostic and Mechanistic Role of the Cuproptosis-Related Genes SMOC2/THY1 in Liver Fibrosis.","date":"2026","source":"Journal of cellular and molecular medicine","url":"https://pubmed.ncbi.nlm.nih.gov/41998832","citation_count":0,"is_preprint":false},{"pmid":"33892290","id":"PMC_33892290","title":"An iPS cell line SDUBMSi0011-A from a multiple epiphyseal dysplasia patient carrying c. 1076T > G mutation in the SMOC2 gene.","date":"2021","source":"Stem cell research","url":"https://pubmed.ncbi.nlm.nih.gov/33892290","citation_count":0,"is_preprint":false},{"pmid":"41720157","id":"PMC_41720157","title":"Prussian blue nanozymes alleviate postoperative pain via upregulating endogenous SMOC2 secretion in dorsal root ganglion fibroblasts.","date":"2026","source":"Journal of advanced research","url":"https://pubmed.ncbi.nlm.nih.gov/41720157","citation_count":0,"is_preprint":false},{"pmid":null,"id":"bio_10.1101_2025.04.17.647851","title":"Molecular and Epigenetic Pathways Underlying Epithelial Damage and Repair in Necrotizing Enterocolitis via Multi-omics Approach","date":"2025-04-22","source":"bioRxiv","url":"https://doi.org/10.1101/2025.04.17.647851","citation_count":0,"is_preprint":true},{"pmid":null,"id":"bio_10.1101_2025.03.05.641653","title":"Immune signaling mediates stromal changes to support epithelial reprogramming in Celiac duodenum","date":"2025-03-10","source":"bioRxiv","url":"https://doi.org/10.1101/2025.03.05.641653","citation_count":0,"is_preprint":true}],"cost":{"stage1":{"model":"claude-sonnet-4-6","input_tokens":30742,"output_tokens":6748,"usd":0.096723,"stage1_stop_reason":"end_turn"},"stage2":{"model":"claude-opus-4-8","input_tokens":15801,"output_tokens":7233,"usd":0.129915,"stage2_stop_reason":"end_turn"},"total_usd":0.226638,"stage1_batch_id":"msgbatch_013LWZZT6MWaqB9qyTSeQBmU","stage2_batch_id":"msgbatch_0194ZzQaTGNpruoNJBbEMbt3","note":"batch pricing = 50% of standard"},"stage1_raw":"```json\n{\n  \"discoveries\": [\n    {\n      \"year\": 2003,\n      \"finding\": \"SMOC2 is a secreted modular glycoprotein containing an EF-hand calcium-binding domain homologous to BM-40, two thyroglobulin-like domains, a follistatin-like domain, and a novel SMOC-specific domain. Recombinant protein analysis showed it has a calcium-dependent conformation.\",\n      \"method\": \"Recombinant protein expression, domain analysis, calcium-binding characterization\",\n      \"journal\": \"The Biochemical journal\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1 / Moderate — direct biochemical characterization of recombinant protein with domain mapping and calcium-binding assay in a dedicated study\",\n      \"pmids\": [\"12741954\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2006,\n      \"finding\": \"SMOC2 is localized to the extracellular periphery of endothelial cells and secreted into culture medium. Overexpression potentiates VEGF- and bFGF-induced DNA synthesis and angiogenic network formation; siRNA knockdown inhibits endothelial cell proliferation and network formation. In vivo, SMOC2 synergizes with bFGF to promote cell invasion into Matrigel plugs.\",\n      \"method\": \"Adenoviral overexpression, siRNA knockdown, DNA synthesis assay, in vitro Matrigel angiogenesis assay, subdermal Matrigel plug assay in mice\",\n      \"journal\": \"The Journal of biological chemistry\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple functional assays (gain and loss of function) in single lab, no mechanistic receptor identification\",\n      \"pmids\": [\"16774925\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2007,\n      \"finding\": \"SMOC2 promotes growth factor-induced cyclin D1 expression and DNA synthesis by maintaining integrin-linked kinase (ILK) activity during G1. SMOC2 ablation reduces ILK activity without affecting PDGFβR autophosphorylation or MAPK/Akt activation; ectopic hyperactive ILK rescues the mitogenic defect in SMOC2-deficient cells. Cyclin D1 overexpression also rescues G1 progression in SMOC2-deficient cells, placing cyclin D1 downstream of the SMOC2-ILK axis.\",\n      \"method\": \"siRNA knockdown, ILK activity assay, cyclin D1 expression analysis, epistasis rescue experiments with hyperactive ILK and cyclin D1 overexpression, DNA synthesis assay\",\n      \"journal\": \"Molecular biology of the cell\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — reciprocal gain/loss-of-function with epistasis rescue, multiple orthogonal readouts in single lab\",\n      \"pmids\": [\"17989364\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"SMOC2 stimulates attachment of primary epidermal keratinocytes and keratinocyte-derived cell lines via αvβ6 and αvβ1 integrins. Integrin blocking antibodies identify these as key receptors. The extracellular calcium-binding domain mediates both cell attachment, focal adhesion formation, and cell migration, but not proliferation.\",\n      \"method\": \"Cell attachment assay with recombinant protein, integrin-blocking antibody experiments, focal adhesion imaging, migration assay, domain deletion analysis\",\n      \"journal\": \"Experimental cell research\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — direct biochemical domain mapping combined with functional blocking antibody experiments identifying specific integrin receptors\",\n      \"pmids\": [\"18582461\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2008,\n      \"finding\": \"SMOC2 expression is transcriptionally repressed by activated aryl-hydrocarbon receptor (AHR) signaling. The SMOC2 promoter contains consensus AHR-binding sites, and AHR ligands (benzo[a]pyrene, TCDD) repress SMOC2 promoter-driven reporter activity in an AHR-dependent manner. TCDD represses Smoc2 mRNA in Ahr+/+ but not Ahr-/- mouse testes in organ culture.\",\n      \"method\": \"Promoter-reporter assay, AHR ligand treatment, Ahr knockout organ culture, RT-PCR\",\n      \"journal\": \"Gene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — promoter reporter + genetic (Ahr KO) validation in single lab, two orthogonal approaches\",\n      \"pmids\": [\"19146932\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2009,\n      \"finding\": \"Smoc2 expression in the fetal gonad is dependent on Hedgehog signaling: organ culture experiments show that Smoc2 expression in testes, mesonephroi, and kidneys requires Hedgehog pathway activity. Smoc2 is expressed in Leydig cells and mesonephroi but not in wildtype ovaries, indicating sexually dimorphic regulation.\",\n      \"method\": \"Organ culture with Hedgehog pathway inhibition, in situ hybridization, transgenic mutant analysis\",\n      \"journal\": \"Developmental dynamics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — organ culture functional experiments with pathway inhibition, single lab\",\n      \"pmids\": [\"19842175\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2011,\n      \"finding\": \"Loss-of-function of SMOC2 in zebrafish (smoc2 knockdown) causes pharyngeal tooth abnormalities resembling the human dentin dysplasia phenotype and reduces expression of key odontogenesis genes dlx2, bmp2, and pitx2, placing SMOC2 upstream of these odontogenic transcription factors.\",\n      \"method\": \"Morpholino knockdown in zebrafish, in situ hybridization for odontogenesis genes\",\n      \"journal\": \"American journal of human genetics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — morpholino knockdown with defined molecular phenotype (gene expression changes), single lab\",\n      \"pmids\": [\"22152679\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2014,\n      \"finding\": \"Smoc2 morpholino knockdown in zebrafish impairs myelopoiesis: hemangioblast development and myeloid progenitor specification are disrupted, and BMP target genes are downregulated in smoc2 morphants, placing Smoc2 upstream of BMP target gene transcription during embryonic myeloid development.\",\n      \"method\": \"Morpholino knockdown in zebrafish, molecular marker analysis (in situ hybridization), BMP target gene expression analysis\",\n      \"journal\": \"Developmental dynamics\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — morpholino loss-of-function with epistatic placement upstream of BMP targets, single lab\",\n      \"pmids\": [\"25044883\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2015,\n      \"finding\": \"SMOC2 expression is induced downstream of L1-ezrin-NF-κB signaling in colorectal cancer cells. SMOC2 is required for L1-mediated increases in cell motility, proliferation under stress, and liver metastasis. SMOC2 promotes a mesenchymal phenotype by decreasing E-cadherin and increasing Snail via integrin-linked kinase (ILK) signaling, and elevates Lgr5 expression.\",\n      \"method\": \"siRNA knockdown, overexpression, cell motility assay, liver metastasis mouse model, western blot for E-cadherin/Snail/ILK\",\n      \"journal\": \"Oncogene\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — epistasis (L1→SMOC2→ILK→EMT) established by gain/loss of function and in vivo metastasis model, single lab\",\n      \"pmids\": [\"25915847\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"SMOC2 is upregulated in kidney tubular epithelial cells following fibrosis and critically mediates fibroblast-to-myofibroblast transition (FMT): SMOC2 activates stress fiber formation, proliferation, migration, and ECM production in fibroblasts. siRNA targeting SMOC2 attenuates TGFβ1-mediated FMT in vitro and kidney fibrosis in mice.\",\n      \"method\": \"Genetically manipulated mice (SMOC2 overexpression and knockdown), siRNA in vitro, TGFβ1 stimulation, fibrosis readouts (stress fiber, ECM production, migration)\",\n      \"journal\": \"JCI insight\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple genetic models (OE and KD mice), in vitro mechanistic validation, in vivo disease model, replicated across models\",\n      \"pmids\": [\"28422762\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2017,\n      \"finding\": \"Canine brachycephaly is caused by an intronic retrotransposon insertion in SMOC2 that promotes cryptic splice site usage, drastically reducing SMOC2 gene expression. SMOC2 disruption affects facial skeletal length in a dose-dependent manner, accounting for 36% of facial length variation.\",\n      \"method\": \"Morphometrics, QTL mapping, splice site analysis, transcript quantification in brachycephalic dogs\",\n      \"journal\": \"Current biology\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — QTL mapping with molecular validation of splice disruption and dose-dependent phenotypic effect, single study\",\n      \"pmids\": [\"28552356\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"SMOC2 directly interacts with WNT receptors Fzd6 and LRP6 (co-immunoprecipitation), enhances ligand-receptor interaction with canonical WNT ligands Wnt3a and Wnt10b, and thereby activates the WNT/β-catenin pathway to support endometrial cancer stem cell properties including stemness gene expression (SOX2, OCT4, NANOG) and chemoresistance.\",\n      \"method\": \"Co-immunoprecipitation assay, luciferase reporter assay, siRNA knockdown, sphere formation assay, western blotting\",\n      \"journal\": \"EBioMedicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct Co-IP identifying WNT receptor binding partners plus functional reporter assay, single lab\",\n      \"pmids\": [\"30594556\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2018,\n      \"finding\": \"SMOC2 knockout mice show reduced BLM-induced pulmonary fibrosis with decreased TGFβ1, α-SMA, p-SMAD2, and p-SMAD3 levels. In vitro, SMOC2 upregulation activates fibrosis in MRC-5 cells, and SMOC2 knockdown reduces TGFβ1-stimulated p-SMAD2 and p-SMAD3, placing SMOC2 upstream of the TGFβ1/SMAD2/3 signaling axis.\",\n      \"method\": \"SMOC2 knockout mice, BLM-induced pulmonary fibrosis model, siRNA knockdown in vitro, western blot for SMAD phosphorylation\",\n      \"journal\": \"Biomedicine & pharmacotherapy\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mouse model plus in vitro mechanistic validation, single lab\",\n      \"pmids\": [\"30021376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"A SMOC2 missense mutation (c.1076T>G, Leu359Arg) prevents binding of SMOC2 to COL9A1 and HSPG, and causes the mutant protein to competitively bind BMPR1B, thereby inhibiting BMP-SMAD1/5/9 signaling and producing growth plate defects (disorganized proliferative zones, expanded hypertrophic zones) and short-limbed dwarfism in knock-in mice.\",\n      \"method\": \"Knock-in mouse model, in vivo and in vitro BMP-SMAD signaling assays, protein binding assays (SMOC2 vs COL9A1/HSPG/BMPR1B interactions)\",\n      \"journal\": \"Bone\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Moderate — knock-in mouse with mutagenesis, in vivo pathway analysis, and direct binding partner identification by multiple methods\",\n      \"pmids\": [\"33059102\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"SMOC2 triggers EMT in kidney epithelial cells through the integrin β3, FAK, and paxillin pathway. Recombinant and enforced SMOC2 expression increases EMT markers, matrix production, proliferation, and migration in RCC cell lines, all inhibited by SMOC2 siRNA.\",\n      \"method\": \"Recombinant protein treatment, enforced expression, siRNA knockdown, western blot for integrin β3/FAK/paxillin/EMT markers, in vivo xenograft\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain and loss of function plus in vivo validation with pathway identification, single lab\",\n      \"pmids\": [\"35869056\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2020,\n      \"finding\": \"Smoc2 deficiency in mice results in age-induced periodontal bone loss, impaired bone healing after tooth avulsion, and increased osteoclast activity/bone resorption. Smoc2-GFP reporter marks dental and bone progenitors and is reactivated after tooth injury. COX2 inhibitor (ibuprofen) blocks injury-induced bone loss in Smoc2-/- mice by reducing MMP9.\",\n      \"method\": \"Smoc2 knockout mouse model, GFP reporter, micro-CT, histology, pharmacological COX2 inhibition, MMP9 analysis\",\n      \"journal\": \"Scientific reports\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — KO mouse with reporter plus pharmacological rescue, single lab\",\n      \"pmids\": [\"32908163\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"Smoc1 and Smoc2 are downstream transcriptional targets of Runx2 in osteoblasts. Runx2 upregulates both genes; knockdown of Smoc1 or Smoc2 inhibits osteoblastogenesis. Smoc2 KO mice show mild craniofacial phenotypes, and Smoc1/Smoc2 double KO mice have severe defects including absent skull, shortened tibiae, and impaired endochondral bone formation.\",\n      \"method\": \"RNA-sequencing, siRNA knockdown, single and double KO mouse models, skeletal phenotyping\",\n      \"journal\": \"Communications biology\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — transcriptomic identification validated by multiple KO models including double KO with severe epistatic phenotype, multiple orthogonal methods\",\n      \"pmids\": [\"34667264\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2021,\n      \"finding\": \"SMOC2 promotes TGFβ1-induced fibroblast-to-myofibroblast transformation (FMT) in lung fibroblasts by activating AKT and ERK signaling. Inhibition of AKT or ERK reverses the promoting effects of SMOC2 overexpression on proliferation, migration, and FMT.\",\n      \"method\": \"Overexpression, western blot for p-AKT/p-ERK, AKT/ERK inhibitor rescue experiments, proliferation and migration assays\",\n      \"journal\": \"Hereditas\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — gain-of-function with pharmacological pathway rescue, single lab\",\n      \"pmids\": [\"34876240\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SMOC2 is secreted by DRG fibroblasts to form a component of the basement membrane surrounding DRG neuron-satellite glial cell units. SMOC2 directly interacts with P2X7 receptor and suppresses ATP-induced P2X7R activation in HEK293 cells. Smoc2 KO increases coupled activation of adjacent DRG neurons in response to nociceptive mechanical stimuli, raising mechanical sensitivity. DRG injection of A740003 (P2X7R antagonist) does not further enhance SMOC2-inhibited coupling, placing SMOC2 upstream of P2X7R-mediated neuronal communication.\",\n      \"method\": \"Smoc2 KO mice, Smoc2 knockdown, in vivo calcium imaging of DRG neurons, HEK293 P2X7R expression with SMOC2 co-expression, DRG injection of recombinant SMOC2 and P2X7R antagonist, behavioral testing\",\n      \"journal\": \"The Journal of neuroscience\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 2 / Strong — multiple orthogonal methods (KO, KD, rescue, heterologous expression, pharmacological epistasis, in vivo imaging) in single rigorous study\",\n      \"pmids\": [\"35437277\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2022,\n      \"finding\": \"SMOC2 promotes migration and invasion of RA fibroblast-like synoviocytes by controlling MYO1C expression through two mechanisms: SOX4-mediated transcriptional regulation and ALKBH5-mediated m6A post-transcriptional modification, leading to cytoskeletal remodeling.\",\n      \"method\": \"siRNA knockdown, transcriptomics, Co-IP, m6A modification analysis, in vitro migration/invasion assays, in vivo collagen-induced arthritis model with intra-articular shRNA\",\n      \"journal\": \"Cell death & disease\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — multiple mechanistic layers (transcriptional + m6A) identified in single lab, in vivo validation\",\n      \"pmids\": [\"36513634\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SMOC2 promotes cardiac fibrosis through the ILK/p38 signaling pathway. SMOC2 knockdown inhibits TGFβ-induced cardiac fibroblast transdifferentiation and collagen deposition. ILK overexpression increases p38 phosphorylation and reverses the protective effect of SMOC2 silencing, establishing ILK→p38 as the downstream effector axis.\",\n      \"method\": \"AAV9-shRNA knockdown in mice, ISO-induced cardiac fibrosis model, TGFβ-treated neonatal fibroblasts, ILK overexpression rescue, western blot for ILK/p-p38\",\n      \"journal\": \"Frontiers in cardiovascular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — in vivo KD and in vitro epistasis rescue with defined pathway, single lab\",\n      \"pmids\": [\"36935650\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2023,\n      \"finding\": \"SMOC2 potentiates BMP9-induced osteogenic differentiation in mesenchymal stem cells by enhancing FAK/PI3K/AKT signaling. Integrin β1 interacts with SMOC2 in BMP9-treated cells. GTF2I is enriched at the SMOC2 promoter. SMOC2 knockdown or FAK silencing reduces BMP9-induced osteogenic markers, and LY294002 (PI3K inhibitor) partially abolishes SMOC2-enhanced osteogenesis.\",\n      \"method\": \"Overexpression, siRNA knockdown, Co-IP (integrin β1–SMOC2), ChIP (GTF2I at SMOC2 promoter), PI3K inhibitor, in vitro osteogenesis assay, ectopic bone formation in vivo\",\n      \"journal\": \"Stem cells international\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP plus pharmacological epistasis, single lab, multiple supporting assays\",\n      \"pmids\": [\"36698376\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2025,\n      \"finding\": \"METTL3 increases SMOC2 mRNA stability by adding m6A methylation to SMOC2 transcripts, thereby promoting cardiac fibroblast proliferation and differentiation after hypoxia and cardiac fibrosis post-MI. METTL3 knockdown reduces m6A levels on SMOC2 mRNA and decreases SMOC2 expression, while actinomycin D chase experiments confirm reduced mRNA stability.\",\n      \"method\": \"meRIP-Seq, actinomycin D mRNA stability assay, AAV9-shRNA in vivo KD, western blot, Masson staining\",\n      \"journal\": \"Journal of cellular and molecular medicine\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — direct m6A-seq identification of SMOC2 as METTL3 target plus mRNA stability assay and in vivo validation, single lab\",\n      \"pmids\": [\"40913254\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"SMOC2 protects renal tubular cells during acute kidney injury by interacting with integrin β3 (ITGB3), which restrains the CCND1-CDK4/6 axis, arresting tubular cells in G1 phase and facilitating DNA repair. SMOC2 KO exacerbates tubular injury, DNA damage, and apoptosis; recombinant SMOC2 treatment ameliorates injury. CDK4/6 inhibitor palbociclib phenocopies SMOC2 protection, confirming the downstream pathway.\",\n      \"method\": \"SMOC2 KO mice, recombinant SMOC2 treatment, transcriptomic profiling, biochemical binding assays (SMOC2–ITGB3), CDK4/6 inhibitor (palbociclib) rescue, AKI mouse models (AAI and cisplatin)\",\n      \"journal\": \"Molecular biomedicine\",\n      \"confidence\": \"High\",\n      \"confidence_rationale\": \"Tier 1–2 / Strong — KO plus recombinant protein rescue plus pharmacological epistasis, two independent AKI models, transcriptomics + biochemistry\",\n      \"pmids\": [\"41663805\"],\n      \"is_preprint\": false\n    },\n    {\n      \"year\": 2026,\n      \"finding\": \"SMOC2 interacts with integrin αvβ5 in cardiac fibroblasts to inhibit the LKB1/AMPKα/FOXO3 signaling pathway, reducing antioxidant defence and enhancing lipid peroxidation and oxidative stress, thereby promoting cardiac fibrosis after MI. Fibroblast-specific SMOC2 overexpression aggravates fibrosis; SMOC2 KO reduces fibrosis and improves cardiac function.\",\n      \"method\": \"Fibroblast-specific overexpression, SMOC2 KO mice, LAD ligation MI model, RNA sequencing, metabolomics, Co-IP (SMOC2–integrin αvβ5), western blot for LKB1/AMPKα/FOXO3\",\n      \"journal\": \"Journal of advanced research\",\n      \"confidence\": \"Medium\",\n      \"confidence_rationale\": \"Tier 2 / Moderate — Co-IP binding partner plus multi-omics and in vivo genetic models, single lab\",\n      \"pmids\": [\"41825779\"],\n      \"is_preprint\": false\n    }\n  ],\n  \"current_model\": \"SMOC2 is a secreted extracellular calcium-binding matricellular glycoprotein (SPARC/BM-40 family) that regulates cell-matrix interactions, growth factor responses, and cellular signaling through multiple mechanisms: it binds αvβ6/αvβ1 integrins to promote keratinocyte adhesion and migration via its calcium-binding domain; it maintains integrin-linked kinase (ILK) activity to support growth factor-induced cyclin D1 expression and G1 cell cycle progression; it binds WNT co-receptors Fzd6 and LRP6 to potentiate canonical WNT/β-catenin signaling; it interacts with BMPR1B to modulate BMP-SMAD1/5/9 signaling in a concentration- and mutation-dependent manner; it promotes fibroblast-to-myofibroblast transition via TGFβ1/SMAD2/3 and ILK/p38 pathways across multiple tissues; it interacts with integrin β3 (ITGB3) to restrain the CCND1-CDK4/6 axis in renal tubular cells; it drives EMT through integrin β3/FAK/paxillin signaling; it is secreted by DRG fibroblasts to suppress mechanical nociception by interacting with and inhibiting the P2X7 receptor on satellite glial cells; and it is transcriptionally regulated by Runx2 and AHR, and post-transcriptionally stabilized by METTL3-mediated m6A methylation.\"\n}\n```","stage2_raw":"```json\n{\n  \"mechanistic_narrative\": \"SMOC2 is a secreted, calcium-binding modular matricellular glycoprotein of the SPARC/BM-40 family that couples the extracellular matrix to integrin- and growth-factor-driven signaling to regulate cell adhesion, proliferation, fibrosis, and skeletal development [#0, #3]. Its EF-hand extracellular calcium-binding domain adopts a calcium-dependent conformation and mediates keratinocyte attachment, focal adhesion formation, and migration through \\u03b1v\\u03b26 and \\u03b1v\\u03b21 integrins [#0, #3]. A central, recurring mechanism is engagement of integrin receptors to control cell-cycle progression: SMOC2 sustains integrin-linked kinase (ILK) activity to drive growth-factor-induced cyclin D1 expression and G1 progression [#2], whereas in renal tubular cells it binds integrin \\u03b23 (ITGB3) to restrain the CCND1-CDK4/6 axis and arrest cells in G1 to permit DNA repair [#23]. Through integrin \\u03b23/FAK/paxillin signaling and ILK-dependent suppression of E-cadherin, SMOC2 drives epithelial-mesenchymal transition and tumor cell motility [#8, #14]. SMOC2 is a major pro-fibrotic effector across kidney, lung, and heart, mediating TGF\\u03b21/SMAD2/3- and ILK/p38-dependent fibroblast-to-myofibroblast transition [#9, #12, #20]. It also potentiates canonical WNT/\\u03b2-catenin signaling by binding the co-receptors Fzd6 and LRP6 and enhancing WNT ligand-receptor interaction [#11], and modulates BMP signaling: a Leu359Arg missense mutation that abolishes COL9A1/HSPG binding causes SMOC2 to competitively bind BMPR1B, inhibit BMP-SMAD1/5/9 signaling, and produce growth-plate defects and short-limbed dwarfism in knock-in mice [#13]. SMOC2 is a transcriptional target of Runx2 required for osteoblastogenesis [#16] and is post-transcriptionally stabilized by METTL3-mediated m6A methylation [#22]. In sensory ganglia, fibroblast-secreted SMOC2 binds and inhibits the P2X7 receptor on satellite glial cells to suppress coupled nociceptive neuronal activation [#18].\",\n  \"teleology\": [\n    {\n      \"year\": 2003,\n      \"claim\": \"Established SMOC2 as a secreted modular glycoprotein and defined its domain architecture, providing the structural basis for its matricellular function.\",\n      \"evidence\": \"Recombinant protein expression with domain mapping and calcium-binding characterization\",\n      \"pmids\": [\"12741954\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"No receptor or binding partner identified at this stage\", \"Functional consequence of calcium-dependent conformation untested\"]\n    },\n    {\n      \"year\": 2006,\n      \"claim\": \"Showed SMOC2 functionally potentiates growth-factor-induced endothelial proliferation and angiogenesis, moving it from a structural ECM component to a modulator of growth-factor responses.\",\n      \"evidence\": \"Adenoviral overexpression, siRNA knockdown, Matrigel angiogenesis and plug assays in mice\",\n      \"pmids\": [\"16774925\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No receptor mediating the angiogenic effect identified\", \"Mechanism linking SMOC2 to VEGF/bFGF signaling unresolved\"]\n    },\n    {\n      \"year\": 2007,\n      \"claim\": \"Defined the SMOC2-ILK-cyclin D1 axis, explaining how SMOC2 promotes G1 cell-cycle progression downstream of growth factors.\",\n      \"evidence\": \"siRNA knockdown with ILK activity assay and epistasis rescue by hyperactive ILK and cyclin D1\",\n      \"pmids\": [\"17989364\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"How SMOC2 maintains ILK activity mechanistically unclear\", \"Upstream receptor coupling SMOC2 to ILK not defined here\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Identified the specific integrin receptors (\\u03b1v\\u03b26, \\u03b1v\\u03b21) and the calcium-binding domain as the structural determinant for SMOC2-mediated adhesion and migration, separating adhesion/migration from proliferation.\",\n      \"evidence\": \"Cell attachment, integrin blocking antibodies, focal adhesion imaging, and domain deletion in keratinocytes\",\n      \"pmids\": [\"18582461\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Did not connect integrin engagement to the ILK/cyclin D1 axis\", \"Cell-type specificity of integrin usage untested\"]\n    },\n    {\n      \"year\": 2008,\n      \"claim\": \"Placed SMOC2 transcription under negative control of AHR signaling, identifying an environmental/ligand-responsive regulatory input.\",\n      \"evidence\": \"Promoter-reporter assay, AHR ligand treatment, and Ahr-knockout organ culture\",\n      \"pmids\": [\"19146932\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct AHR binding to the SMOC2 promoter not shown by ChIP\", \"Physiological context of AHR repression unclear\"]\n    },\n    {\n      \"year\": 2009,\n      \"claim\": \"Showed Smoc2 expression in the fetal gonad/kidney is Hedgehog-dependent and sexually dimorphic, embedding SMOC2 in developmental signaling pathways.\",\n      \"evidence\": \"Organ culture with Hedgehog inhibition, in situ hybridization, transgenic mutant analysis\",\n      \"pmids\": [\"19842175\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct vs indirect Hedgehog regulation not distinguished\", \"Functional consequence of gonadal Smoc2 expression untested\"]\n    },\n    {\n      \"year\": 2011,\n      \"claim\": \"Established SMOC2 as functionally required for tooth development, placing it upstream of odontogenic transcription factors and linking it to human dentin dysplasia.\",\n      \"evidence\": \"Morpholino knockdown in zebrafish with in situ hybridization for dlx2, bmp2, pitx2\",\n      \"pmids\": [\"22152679\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular intermediary between SMOC2 and odontogenic genes unknown\", \"Morpholino approach lacks genetic confirmation\"]\n    },\n    {\n      \"year\": 2014,\n      \"claim\": \"Extended SMOC2's developmental role to embryonic myelopoiesis and placed it upstream of BMP target gene transcription.\",\n      \"evidence\": \"Morpholino knockdown in zebrafish with marker and BMP target gene analysis\",\n      \"pmids\": [\"25044883\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Mechanism linking SMOC2 to BMP signaling not biochemically defined\", \"Conservation in mammalian hematopoiesis untested\"]\n    },\n    {\n      \"year\": 2015,\n      \"claim\": \"Identified SMOC2 as a pro-metastatic effector in colorectal cancer that drives EMT via ILK signaling, integrating its adhesion biology with tumor progression.\",\n      \"evidence\": \"siRNA/overexpression, motility assays, liver metastasis mouse model, EMT marker western blot\",\n      \"pmids\": [\"25915847\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct receptor engagement in colorectal cells not shown\", \"Single-lab in vivo metastasis model\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Established SMOC2 as a critical mediator of fibroblast-to-myofibroblast transition and kidney fibrosis downstream of TGF\\u03b21, defining its central pro-fibrotic role.\",\n      \"evidence\": \"SMOC2 overexpression and knockdown mice, siRNA in vitro, TGF\\u03b21 stimulation, fibrosis readouts\",\n      \"pmids\": [\"28422762\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Receptor coupling SMOC2 to TGF\\u03b21/SMAD response not defined here\", \"Whether effect is cell-autonomous to fibroblasts unresolved\"]\n    },\n    {\n      \"year\": 2017,\n      \"claim\": \"Demonstrated dose-dependent control of facial skeletal length by SMOC2 expression via a natural splice-disrupting insertion, providing in vivo evidence for SMOC2 in craniofacial morphogenesis.\",\n      \"evidence\": \"QTL mapping, splice analysis, transcript quantification in brachycephalic dogs\",\n      \"pmids\": [\"28552356\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular pathway connecting SMOC2 dosage to bone length unclear\", \"Correlational genetics rather than direct mechanism\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Identified direct SMOC2 binding to WNT co-receptors Fzd6 and LRP6 and potentiation of canonical WNT signaling, expanding SMOC2's receptor repertoire beyond integrins.\",\n      \"evidence\": \"Co-immunoprecipitation, luciferase reporter, sphere formation in endometrial cancer cells\",\n      \"pmids\": [\"30594556\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Reciprocal/endogenous interaction validation limited\", \"Binding interface on SMOC2 not mapped\"]\n    },\n    {\n      \"year\": 2018,\n      \"claim\": \"Placed SMOC2 upstream of the TGF\\u03b21/SMAD2/3 axis in pulmonary fibrosis, generalizing its pro-fibrotic mechanism to a second organ.\",\n      \"evidence\": \"SMOC2 knockout mice, BLM fibrosis model, siRNA in vitro, SMAD phosphorylation western blot\",\n      \"pmids\": [\"30021376\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How SMOC2 modulates SMAD phosphorylation mechanistically unknown\", \"Receptor not identified\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Resolved a disease-causing missense mutation mechanism in which loss of COL9A1/HSPG binding redirects SMOC2 to competitively inhibit BMPR1B, linking SMOC2 to BMP-SMAD1/5/9 signaling and skeletal dysplasia.\",\n      \"evidence\": \"Knock-in mouse, in vivo/in vitro BMP-SMAD assays, SMOC2-COL9A1/HSPG/BMPR1B binding assays\",\n      \"pmids\": [\"33059102\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Whether wild-type SMOC2 normally regulates BMPR1B unclear\", \"Stoichiometry of competitive binding not quantified\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Defined an integrin \\u03b23/FAK/paxillin pathway through which SMOC2 drives EMT and matrix production in renal cancer cells.\",\n      \"evidence\": \"Recombinant protein, enforced expression, siRNA, pathway western blots, xenograft\",\n      \"pmids\": [\"35869056\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct SMOC2-ITGB3 binding not biochemically shown here\", \"Single-lab pathway assignment\"]\n    },\n    {\n      \"year\": 2020,\n      \"claim\": \"Established SMOC2 as a marker and functional regulator of dental/bone progenitors and bone homeostasis, with loss causing periodontal bone loss and excess osteoclast activity.\",\n      \"evidence\": \"Smoc2 knockout, GFP reporter, micro-CT, COX2 inhibitor rescue, MMP9 analysis\",\n      \"pmids\": [\"32908163\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Molecular pathway linking SMOC2 to osteoclast/MMP9 control unclear\", \"Cell-autonomous vs paracrine action undefined\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Placed Smoc2 downstream of Runx2 as a transcriptional target required for osteoblastogenesis, with double Smoc1/Smoc2 loss producing severe skeletal defects.\",\n      \"evidence\": \"RNA-seq, siRNA, single and double KO mouse skeletal phenotyping\",\n      \"pmids\": [\"34667264\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Functional redundancy of Smoc1/Smoc2 not molecularly dissected\", \"Downstream effectors in osteoblasts unidentified\"]\n    },\n    {\n      \"year\": 2021,\n      \"claim\": \"Identified AKT and ERK as effector pathways for SMOC2-driven lung fibroblast-to-myofibroblast transformation, broadening its pro-fibrotic signaling outputs.\",\n      \"evidence\": \"Overexpression with AKT/ERK inhibitor rescue and proliferation/migration assays\",\n      \"pmids\": [\"34876240\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Upstream receptor not defined\", \"Gain-of-function only\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Demonstrated SMOC2 is secreted into the DRG basement membrane and directly binds and inhibits the P2X7 receptor on satellite glia to suppress mechanical nociception, revealing a neuro-immune signaling role.\",\n      \"evidence\": \"Smoc2 KO/KD, in vivo calcium imaging, HEK293 P2X7R co-expression, pharmacological epistasis, behavior\",\n      \"pmids\": [\"35437277\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Structural basis of SMOC2-P2X7R inhibition not resolved\", \"Generality beyond DRG untested\"]\n    },\n    {\n      \"year\": 2022,\n      \"claim\": \"Revealed dual transcriptional (SOX4) and m6A (ALKBH5) control of MYO1C as the mechanism for SMOC2-driven synoviocyte invasion in rheumatoid arthritis.\",\n      \"evidence\": \"siRNA, transcriptomics, Co-IP, m6A analysis, migration/invasion assays, CIA model\",\n      \"pmids\": [\"36513634\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"How SMOC2 controls SOX4/ALKBH5 mechanistically unclear\", \"Multiple layers attributed in a single study\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Defined the ILK/p38 axis as the downstream effector of SMOC2-driven cardiac fibrosis, extending its pro-fibrotic role to heart.\",\n      \"evidence\": \"AAV9-shRNA in mice, ISO fibrosis model, TGF\\u03b2-treated fibroblasts, ILK overexpression rescue\",\n      \"pmids\": [\"36935650\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Receptor linking SMOC2 to ILK in cardiac fibroblasts unknown\", \"Single-lab assignment\"]\n    },\n    {\n      \"year\": 2023,\n      \"claim\": \"Showed SMOC2 potentiates BMP9 osteogenesis through integrin \\u03b21-coupled FAK/PI3K/AKT signaling and is itself transcriptionally controlled by GTF2I, integrating integrin engagement with osteogenic differentiation.\",\n      \"evidence\": \"Overexpression/siRNA, Co-IP (integrin \\u03b21), ChIP (GTF2I), PI3K inhibitor, in vivo bone formation\",\n      \"pmids\": [\"36698376\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct integrin \\u03b21-SMOC2 interface not mapped\", \"Single-lab pathway\"]\n    },\n    {\n      \"year\": 2025,\n      \"claim\": \"Identified METTL3-mediated m6A methylation as a stabilizer of SMOC2 mRNA driving post-MI cardiac fibrosis, adding a post-transcriptional layer to SMOC2 regulation.\",\n      \"evidence\": \"meRIP-Seq, actinomycin D stability assay, AAV9-shRNA in vivo, Masson staining\",\n      \"pmids\": [\"40913254\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"m6A reader mediating stabilization not identified\", \"Single-lab finding\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Showed SMOC2 binds integrin \\u03b23 to restrain the CCND1-CDK4/6 axis and arrest renal tubular cells in G1, protecting against acute kidney injury \\u2014 a cytoprotective, anti-proliferative role contrasting its pro-proliferative ILK action.\",\n      \"evidence\": \"SMOC2 KO, recombinant protein rescue, transcriptomics, SMOC2-ITGB3 binding, palbociclib epistasis, two AKI models\",\n      \"pmids\": [\"41663805\"],\n      \"confidence\": \"High\",\n      \"gaps\": [\"Reconciliation with SMOC2's pro-proliferative ILK/cyclin D1 role across cell types unresolved\", \"Determinants of pro- vs anti-proliferative output unknown\"]\n    },\n    {\n      \"year\": 2026,\n      \"claim\": \"Identified SMOC2-integrin \\u03b1v\\u03b25 engagement as an inhibitor of LKB1/AMPK\\u03b1/FOXO3 antioxidant signaling that enhances lipid peroxidation and post-MI cardiac fibrosis, linking SMOC2 to redox/metabolic control.\",\n      \"evidence\": \"Fibroblast-specific overexpression, SMOC2 KO, LAD ligation MI, RNA-seq, metabolomics, Co-IP (\\u03b1v\\u03b25)\",\n      \"pmids\": [\"41825779\"],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"Direct binding interface with \\u03b1v\\u03b25 not mapped\", \"Single-lab multi-omics correlation\"]\n    },\n    {\n      \"year\": null,\n      \"claim\": \"It remains unclear what molecular switch determines whether integrin-engaged SMOC2 drives pro-proliferative ILK/cyclin D1 signaling versus anti-proliferative CCND1-CDK4/6 restraint, and how its many integrin partners (\\u03b1v\\u03b26, \\u03b1v\\u03b21, \\u03b23, \\u03b21, \\u03b1v\\u03b25) are selected in a given cell type.\",\n      \"evidence\": \"\",\n      \"pmids\": [],\n      \"confidence\": \"Medium\",\n      \"gaps\": [\"No unified structural model of SMOC2-integrin selectivity\", \"Context-dependent opposite cell-cycle outcomes unexplained\", \"No high-resolution structure of SMOC2 bound to any receptor\"]\n    }\n  ],\n  \"mechanism_profile\": {\n    \"molecular_activity\": [\n      {\"term_id\": \"GO:0098772\", \"supporting_discovery_ids\": [2, 11, 13, 18, 23]},\n      {\"term_id\": \"GO:0008092\", \"supporting_discovery_ids\": [3, 14]},\n      {\"term_id\": \"GO:0005198\", \"supporting_discovery_ids\": [0, 18]},\n      {\"term_id\": \"GO:0060089\", \"supporting_discovery_ids\": [3, 14, 23, 24]}\n    ],\n    \"localization\": [\n      {\"term_id\": \"GO:0005576\", \"supporting_discovery_ids\": [0, 1, 18]},\n      {\"term_id\": \"GO:0031012\", \"supporting_discovery_ids\": [13, 18]}\n    ],\n    \"pathway\": [\n      {\"term_id\": \"R-HSA-162582\", \"supporting_discovery_ids\": [11, 13, 20, 24]},\n      {\"term_id\": \"R-HSA-1474244\", \"supporting_discovery_ids\": [9, 12, 20]},\n      {\"term_id\": \"R-HSA-1266738\", \"supporting_discovery_ids\": [6, 13, 16]},\n      {\"term_id\": \"R-HSA-1640170\", \"supporting_discovery_ids\": [2, 23]},\n      {\"term_id\": \"R-HSA-1643685\", \"supporting_discovery_ids\": [8, 13, 14, 23]}\n    ],\n    \"complexes\": [],\n    \"partners\": [\"ITGB3\", \"ITGB1\", \"ITGAV\", \"FZD6\", \"LRP6\", \"BMPR1B\", \"P2RX7\", \"COL9A1\"],\n    \"other_free_text\": []\n  }\n}\n```","audit_flag":null,"evaluation":{"pairwise":"win","faith_supported":8,"faith_total":8,"faith_pct":100.0}}